CMS grants NTAP reimbursement status for Abeona gene therapy ZEVASKYN under FY2027 IPPS rule

Reuters2026/08/04 11:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

CMS granted New Technology Add-On Payment status for ZEVASKYN under the FY2027 Hospital Inpatient Prospective Payment System final rule.
NTAP provides supplemental Medicare reimbursement above standard hospital inpatient payments, supporting access to the gene therapy in eligible cases.
Decision strengthens Medicare reimbursement alongside ZEVASKYN’s permanent J-code, supporting coverage for Medicare patients, including those with qualifying disabilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abeona Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040730PRIMZONEFULLFEED9802985) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

CMS grants NTAP reimbursement status for Abeona gene therapy ZEVASKYN under FY2027 IPPS rule

You may also like

Crypto prices